241 results
Page 4 of 13
8-K
EX-99.1
s7qm2iq4 it
2 May 19
BIOTIME presentS UPDATED DATA FROM OPREGENĀ® PHASE i/IIA CLINICAL STUDY AT THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY ANNUAL MEETING
9:00am
8-K
EX-99.1
p8z2i0g7u
29 Apr 19
BIOTIME TO PRESENT SCiSTAR CLINICAL STUDY TOP-LINE DATA AT THE 26TH ANNUAL AMERICAN SOCIETY FOR NEURAL THERAPY AND REPAIR CONFERENCE
9:00am
8-K
EX-99.1
ane5nsm3u r9d
14 Mar 19
BioTime ReportS FOURTH Quarter AND FULL YEAR 2018 Financial Results
4:37pm
8-K
EX-99.1
28npfrq 12
14 Feb 19
BIOTIME PROVIDES BUSINESS UPDATE including information ON agex, ONCOCYTE and ASTERIAS
8:05am
424B3
biuwex5
4 Feb 19
Prospectus supplement
5:52pm
S-4/A
1uhsv1
14 Jan 19
Registration of securities issued in business combination transactions (amended)
12:00am
S-4
rvark
4 Jan 19
Registration of securities issued in business combination transactions
5:05pm
425
zm6b4y
8 Nov 18
Business combination disclosure
9:54pm
425
EX-2.1
de7i45fohuqjb
8 Nov 18
Business combination disclosure
6:41am
425
EX-99.1
k5sk96xs
8 Nov 18
Business combination disclosure
6:41am
8-K
EX-99.1
cvw2yccx87 ut
8 Nov 18
BioTime and ASTERIAS BIOTHERAPEUTICS enter into definitive merger agreement TO CREATE leading cell therapy company
6:41am
8-K
EX-2.1
sothv9av
8 Nov 18
BioTime and ASTERIAS BIOTHERAPEUTICS enter into definitive merger agreement TO CREATE leading cell therapy company
6:41am
8-K
EX-99.1
ywhudu
2 Aug 18
BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
4:13pm
8-K
EX-99.1
nk27t0wxxgn0
10 May 18
BioTime Reports First Quarter Results and Recent Corporate Accomplishments
4:24pm